 |
|
|
| |
Immune-Related AEs After Low-Dose, Finite-Duration Budigalimab ± Trosunilimab in People With HIV
|
| |
| |
CROI 2026 Feb 22-25 Denver
Katharine Bar,1 Manal Abunimeh,2 Claudia Martorell,3 Heide Betman,2 Ana Gabriela Pires dos Santos,2 Shawn Hassler,4 Theo Hodge,5 Simiso Mandisa Sokhela,7 Alireza Farabi,7 Kimmie Pringle,2
Andrew Topp,2 John Marcinak,2 Sharon R. Lewin8
1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 2AbbVie Inc., North Chicago, IL, USA; 3The Research Institute, Springfield, MA, USA; 4Optimus Medical Group, San Francisco, USA;
5Washington Health Institute, Washington DC, USA ; 6Ezintsha, University of the Witwatersrand, Johannesburg, South Africa; 7Division of Infectious Diseases (AF), University Medical Center of Southern Nevada, Las Vegas, NV, USA; 8Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia
|
| |
|
|
|
|
|
